An Observational Study of Patients With Chronic Hepatitis C Undergoing Treatment With PegIntron and Rebetol in Clinical Practice in Belgium (Study P05494)(WITHDRAWN)

Study Overview
=================
Brief Summary
-----------------
This is an observational study of patients undergoing treatment with PegIntron and Rebetol for chronic hepatitis C in clinical practice in Belgium. Treatment will not be administered as part of the study. Safety parameters will be assessed retrospectively. Efficacy parameters, such as relapse rates and sustained virologic response rates, will be assessed prospectively. The objective of the study is to examine any associations between safety, virologic, histologic, demographic parameters and patient outcome (relapse rates and sustained virologic response rates).

Official Title
-----------------
An Observational Multi-Center Study Exploring the Association of Safety, Patient Characteristics, Virological, and Histological Parameters With Patient Outcome (Relapse Rate, Achievement of Sustained Viral Response in Daily Clinical Practice in Belgium- PEGIMPACT

Conditions
-----------------
Hepatitis C, Chronic, Hepatitis C

Intervention / Treatment
-----------------
* Biological: PegIntron (peginterferon alfa-2b; SCH 54031)
* Drug: Rebetol (ribavirin; SCH 18908)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female adult (18 years or older) subjects for whom the treating physician has decided to start treatment with PegIntron® and Rebetol® and reaching the End-of-Treatment time point. For the prospective component, evidence of treatment response at EOT after a complete course of therapy as per SmPC. Subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent. Subjects must be diagnosed with chronic hepatitis C (genotypes 1, 2, 3, 4, 5 or 6). Subjects must be free of any clinically significant disease that would interfere with study participation. Exclusion Criteria: For prospective component of the study: patients not achieving End-of-Treatment response after a complete course of therapy as per SmPC.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Arm 1<br>Patients with chronic hepatitis C treated with PegIntron and Rebetol in clinical practice in Belgium. | Biological: PegIntron (peginterferon alfa-2b; SCH 54031)<br>* PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)<br>* Other names: SCH 54031;Drug: Rebetol (ribavirin; SCH 18908)<br>* Rebetol administered based on body weight 800-1200 mg/day (<65 kg : 800 mg, 65 - 85 kg : 1000 mg, >85 kg : 1200 mg) orally for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)<br>* Other names: SCH 18908;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Safety parameters: common adverse events [AEs], drug-to-drug interaction AEs, and dose modifications |  | Assessed retrospectively in patients treated for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5) and reaching End-of-Treatment. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relapse rates and Sustained Virologic Response (SVR) rates and their association with demographic, virologic, histological, and safety parameters |  | Assessed prospectively at End-of-Treatment (EOT) and 24 weeks post-treatment | 
| Predictors of response at End-of-Treatment |  | Assessed at the End-of-Treatment |